20132 ⎘
Medicinal preparations characterised by special physical form; Pills, tablets, discs, rods; Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
BUPROPION HYDROBROMIDE POLYMORPHS
#302Stable oral benzimidazole compositions and process of preparation thereof
#303Oral solid formulation of compound anti-tubercular drug and preparation method thereof
#304Coated tablet formulation and method
#305DOSAGE FORMS OF ACTIVE INGREDIENTS CONTAINING HYDROXYSTILBENE FOR TREATING MENOPAUSAL COMPLAINTS
#306Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
#307Coating composition suitable for pharmaceutical or nutraceutical dosage forms
#308Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
#309Delayed release drug formulation
#310Method and system using relays with aggregated spectrum
#311Dual release oral tablet compositions of dexlansoprazole
#312Composition comprising a benzimidazole and process for its manufacture
#313Stable corticosteroid nanoparticulate formulations and methods for the making and use thereof
#314Drug Formulations Using Water Soluble Antioxidants
#315High-loading, controlled-release magnesium oral dosage forms and methods for making and using same
#316Multi-layer nicotine-containing pharmaceutical composition
#317Heterogeneous implantable devices for drug delivery
#318Heterogeneous implantable devices for drug delivery
#319Controlled release pharmaceutical compositions of milnacipran
#320Pharmacokinetics of S-adenosylmethionine formulations
#321Enteric tablet
#322Coated capsules and tablets of a fatty acid oil mixture
#323RASAGILINE CITRAMIDE
#324R(+)-N-methyl-propargyl-aminoindan
#325Bupropion hydrobromide polymorphs
#326EXTENDED RELEASE PHARMACEUTICAL COMPOSITIONS CONTAINING PALIPERIDONE
#327SOLID PREPARATION
#328Dosage forms of bisphosphonates
#329SOLID PREPARATION
#330Pharmaceutical composition
#331Technology for Preventing Abuse of Solid Dosage Forms
#332ORGANIC COMPOUNDS
#333DELAYED RELEASE RASAGILINE FORMULATION
#334Press-coated orally-disintegrating tablets
#335SUSTAINED RELEASE CANNABINOID MEDICAMENTS
#336Effective Amounts of (3aR)-1,3a,8-Trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo [2,3-b]indol-5-yl Phenylcarbamate and Methods of Treating or Preventing Neurodegeneration
#337Coated solid dosage forms
#338PHARMACEUTICAL COMPOSITIONS FOR REDUCING ALCOHOL-INDUCED DOSE DUMPING
#339Coated Extended Release Pharmaceutical Compositions Containing Paliperidone
#340DOSAGE FORMS OF ACTIVE INGREDIENTS CONTAINING HYDROXYSTILBENE FOR TREATING MENOPAUSAL COMPLAINTS
#341DRUG COATING PROVIDING HIGH DRUG LOADING AND METHODS FOR PROVIDING THE SAME
#342Abuse resistant oral opioid formulations
#343Abuse resistant forms of immediate release oxycodone, method of use and method of making
#344Immediate release and sustained release ibuprofen dosing regimen
#345Self-breaking tablets
#346Controlled Release Azithromycin Solid Dosage Forms
#347PHARMACEUTICAL FORMULATIONS COMPRISING VALGANCICLOVIR
#348Integrated ingestible event marker system with pharmaceutical product
#349Sustained-Release Tablet and Process for Preparing the Same
#350DELAYED RELEASE RASAGILINE MALATE FORMULATION
#351DOSAGE FORMS OF RISEDRONATE
#352Extended-release oral dosage forms for poorly soluble amine drugs
#353Easily administrable solid preparation
#354MODIFIED RELEASE NIACIN PHARMACEUTICAL FORMULATIONS
#355Pharmaceutical compositions for the coordinated delivery of NSAIDs
#356TABLET SLEEVE FOR IMPROVED PERFORMANCE
#357Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix
#358SOLID PREPARATION
#359Stable pharmaceutical composition for atherosclerosis
#360SOLID PREPARATION
#361NOVEL GASTRO-RETENTIVE DOSAGE FORMS
#362ANTI-ADHESIVE COMPOSITION, SOLID PREPARATION, AND PROCESS FOR PRODUCING THE SAME
#363DELAYED-RELEASE ORAL PHARMACEUTICAL COMPOSITION FOR TREATMENT OF COLONIC DISORDERS
#364METHOD FOR CONTROLLED RELEASE OF AN ACID-UNSTABLE PHYSIOLOGICALLY ACTIVE SUBSTANCE
#365DELAYED RELEASE RASAGILINE FORMULATION
#366Drug coating providing high drug loading and methods for providing the same
#367Solid dosage forms of fenofibrate
#368SPECIFIC TIME-DELAYED BURST PROFILE DELIVERY SYSTEM
#369Dual release oral tablet compositions of dexlansoprazole
#370Enteric formulation of duloxetine and its core and preparation method
#371SYSTEM FOR THE COLON DELIVERY OF DRUGS SUBJECT TO ENZYME DEGRADATION AND/OR POORLY ABSORBED IN THE GASTROINTESTINAL TRACT
#372Stabilized formulations of CNS compounds
#373EXTENDED RELEASE DOSAGE FORM
#374Method of using combination preparation comprising angiotensin-II-receptor blocker and HMG-CoA reductase inhibitor
#375Method Of Treating Attention Deficit Disorders With D-Threo Methylphenidate
#376Coated tablet formulation and method
#377LASER MARKED DOSAGE FORMS
#378CHRONOTHERAPEUTIC PHARMACEUTICAL DOSAGE FORM
#379Controlled release metformin formulations
#380APPETISING MEDICAMENTS FOR ORAL ADMINISTRATION IN SOLID FORM FOR PREVENTION AND/OR TREATMENT OF CARDIAC INSUFFICIENCY IN ANIMALS
#381DOSAGE FORM COMPRISING 1-ISOPROPYL-4-HEXAHYDRO-1H-1,4-DIAZEPINE OR A SALT THEREOF
#382APPETISING MEDICAMENT FOR ORAL ADMINISTRATION IN SOLID FORM
#383Pharmaceutical compositions configured to deter dosage form splitting
#384ORALLY-ADMINISTERED AGENT
#385Hydrophilic/lipophilic polymeric matrix dosage formulation
#386NOVEL DOSAGE FORM OF PALIPERIDONE AND PROCESS FOR PREPARING THE SAME
#387Dosage form containing (S)-pantoprazole as active ingredient
#388Abuse resistant drugs, method of use and method of making
#389Abuse resistant forms of extended release morphine, method of use and method of making
#390Method and system using relays with aggregated spectrum
#391ELVUCITABINE PHARMACEUTICAL COMPOSITIONS
#392QUININE FORMULATIONS, METHOD OF MAKING, AND METHOD OF USE THEREOF
#393Abuse resistant forms of extended release morphine with oxycodone, method of use and method of making
#394Abuse resistant forms of extended release hydrocodone, method of use and method of making
#395QUININE FORMULATIONS, METHOD OF MAKING, AND METHO OF USE THEREOF
#396Abuse resistant forms of extended release oxymorphone, method of use and method of making
#397Abuse resistant forms of extended release oxycodone, method of use, and method of making
#398Abuse resistant forms of extended release hydromorphone, method of use and method of making
#399GASTRO-RESISTANT PHARMACEUTICAL ORAL COMPOSITIONS COMPRISING DULOXETINE OR ITS PHARMACEUTICALLY ACCEPTABLE DERIVATIVES
#400COMPOSITIONS AND METHODS FOR ORAL DRUG DELIVERY
#401SUGAR COATINGS AND METHODS THEREFOR
#402Process
#403Carbidopa/Levodopa gastroretentive drug delivery
#404HUMIDITY-RESISTANT DRUG FORMULATIONS AND METHODS OF PREPARATION THEREOF
#405Magnesium system and use thereof in the cosmetics industry
#406Orally-disintegrating solid preparation
#407Use of a matrix for orally administering sustained release magnesium, and composition containing said matrix
#408COMPOSITIONS COMPRISING EUPHORBIA PROSTRATA AND PROCESS OF PREPARATION THEREOF
#409Rapidly disintegrating gelatinous coated tablets
#410COMBINATIONS OF NIACIN AND AN OXICAM
#411COATING APPARATUS
#412Abuse resistant drugs, method of use and method of making
#413DELAYED RELEASE PHARMACEUTICAL COMPOSITION OF DULOXETINE
#414EXTENDED RELEASE PHARMACEUTICAL COMPOSITION OF PALIPERIDONE
#415Antidepressant Oral Pharmaceutical Compositions
#416PHARMACEUTICAL FORMULATIONS FOR THE ORAL ADMINISTRATION OF PPI
#417Topical formulation
#418Pharmacokinetics of S-adenosylmethionine formulations
#419ORALLY-ADMINISTERED AGENT
#420USE OF 5-AMINOLEVULINIC ACID AND DERIVATIVES IN A SOLID FORM FOR PHOTODYNAMIC TREATMENT AND DIAGNOSIS
#421DELAYED RELEASE COMPOSITIONS OF DULOXETINE
#422PHARMACEUTICAL COMPOSITIONS
#423Stable corticosteroid nanoparticulate formulations and methods for the making and use thereof
#424Abuse resistant oral opioid formulations
#425METHOD AND ARRANGEMENT FOR FORMING VARIABLE COLOR PHARMACEUTICAL PRODUCTS
#426MULTIPLE UNIT PHARMACEUTICAL FORMULATION
#427CONTROLLED RELEASE LAMOTRIGINE FORMULATIONS
#428MILNACIPRAN FORMULATIONS
#429Controlled Release Dosage Formulation of Duloxetine
#430SOLID PHARMACEUTICAL COMPOSITION COMPRISING 1-(4-CHLOROANILINO)-4-(4-PYRIDYLMETHYL)PHTHALAZINE AND A PH MODIFIER
#431Formulations and methods of treating inflammatory bowel disease
#432BUPROPION HYDROBROMIDE AND THERAPEUTIC APPLICATIONS
#433Functionally Coated Breakable Tablets
#434Oral formulations
#435MECHANICAL PROTECTIVE LAYER FOR SOLID DOSAGE FORMS
#436Modified-release formulations of a bupropion salt
#437Pharmaceutical compositions of duloxetine
#438BUPROPION HYDROBROMIDE AND THERAPEUTIC APPLICATIONS
#439Tablet dosage form
#440Citrate salt of Rasagiline
#441Delayed release rasagiline malate formulation
#442Delayed release rasagiline formulation
#443Delayed release rasagiline base formulation
#444Delayed release rasagiline citrate formulation
#445GASTROINTESTINAL-SPECIFIC MULTIPLE DRUG RELEASE SYSTEM
#446Antiretroviral Solid Oral Composition
#447Tablet containing cetirizine, pseudoephedrine, and naproxen containing a barrier layer
#448MEDICAMENT IN A MULTILAYER FORM
#449Oral multi-functional pharmaceutical capsule preparations of proton pump inhibitors
#450DOSAGE FORMS OF RISEDRONATE
#451Low dosage forms of risedronate or its salts
#452Low dosage forms of risedronate or its salts
#453TABLETS AND DISCS WITH COMPARTMENTS WITH TWO OR MORE DRUGS FOR RELEASE AT CERTAIN INTERVALS AND WITH SPECIFIC RATES
#454EXTENDED RELEASE FORMULATIONS OF A PROTON PUMP INHIBITOR
#455Bupropion hydrobromide and therapeutic applications
#456Dosage forms of bisphosphonates
#457SYSTEMIC DELIVERY OF ANTIVIRAL AGENTS
#458High-loading, controlled-release magnesium oral dosage forms and methods of making and using same
#459Anti-diabetic combinations
#460Bupropion hydrobromide polymorphs
#461Ex vivo activatable final dosage form
#462Delayed Release Formulations for Oral Administration of a Polypeptide Therapeutic Agent and Methods of Using Same
#463RELEASE OF STATINS IN THE INTESTINE
#464Stabilized solid preparation
#465ORGANIC COMPOUNDS
#466Method Of Treating Attention Deficit Disorders With D-Threo Methylphenidate
#467TIME-SPECIFIC DELAYED/PULSATILE RELEASE DOSAGE FORMS.
#468Programmable buoyant delivery technology
#469Hydrophilic/lipophilic polymeric matrix dosage formulation
#470METHODS AND COMPOSITIONS FOR PRODUCING ANTI-ANDROGENIC EFFECTS
#471Pharmaceutical formulation
#472Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a NSAID
#473Oral formulations of cytidine analogs and methods of use thereof
#474Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
#475Multilayer Proton Pump Inhibitor Tablets
#476ORAL CONTRACEPTIVE DOSAGE FORMS AND METHODS OF MAKING SUCH DOSAGE FORMS
#477Controlled release delivery device comprising an organosol coat
#478Pharmaceutical compositions comprising non-steroidal antiinflammatory drug, antipyretic-analgesic drug and proton pump inhibitor
#479FORMULATIONS CONTAINING PANTOPRAZOLE FREE ACID AND ITS SALTS
#480PHARMACEUTICAL COMPOSITIONS COMPRISING A PH-DEPENDENT DRUG, A PH MODIFIER AND A RETARDING AGENT
#481Pharmaceutical Composition Of Acid Labile Substances
#482Dip coated compositions containing a starch having a high amylose content
#483Dosage form containing pantoprazole as active ingredient
#484CONTROLLED ABSORPTION OF STATINS IN THE INTESTINE
#485Oral compositions containing a salivation inducing agent
#486METHODS FOR THE DISPERSION OF WATER-SOLUABLE OR HYDROPHILIC SUBSTANCES IN A SUPERCRITICALLY PRESSURIZED FLUID
#487Pharmaceutical formulations of amyloid inhibiting compounds
#488EXTENDED RELEASE TABLET FORMULATION CONTAINING PRAMIPEXOLE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
#489DELAYED-RELEASE ORAL PHARMACEUTICAL COMPOSITION FOR TREATMENT OF COLONIC DISORDERS
#490MESALAZINE TABLET
#491Method of manufacturing modified release dosage forms
#492PULSED-RELEASE PREPARATION HAVING IMPROVED DISINTEGRATION PROPERTIES IN VIVO
#493Zero-Order Modified Release Solid Dosage Forms
#494Extended release compositions of proton pump inhibitors
#495Liposome Drug Delivery of Polycyclic, Aromatic, Antioxidant or Anti-Inflammatory Compounds
#496Chronic, Bolus Adminstration Of D-Threo Methylphenidate
#497Dip coated compositions containing copolymer of polyvinyl alcohol and polyethylene glycol and a gum
#498Azithromycin for treatment of skin disorders
#499Controlled release azithromycin solid dosages forms
#500Immediate release and sustained release ibuprofen dosing regimen
#501Method for producing a drug extract that contains hydroxystilbene
#502METHOD OF MAKING A SINGLE-STAGE PHARMACEUTICAL PREPARATION FOR ORAL THERAPY TO REGULATE BLOOD PRESSURE AND KIT CONTAINING SAME
#503PHARMACEUTICAL COMPOSITION FOR CONTRACEPTION AND BLOOD PRESSURE REGULATION, KIT FOR CONTRACEPTION CONTAINING SAME AND METHOD OF PRODUCTION OF SAME
#504Stable taste masked formulations of cephalosporins
#505Stable pharmaceutical formulation of an acid labile compound and process for preparing the same
#506Nanoparticulate formulations and methods for the making and use therof
#507Duloxetine Formulation
#508Laser Marked Dosage Forms
#509Laser Marked Dosage Forms
#510STABLE ORAL FORMULATION CONTAINING BENZIMIDAZOLE DERIVATIVE
#511Multi-Layer Tablets and Bioadhesive Dosage Forms
#512Solid form
#513Polymer Composition And Dosage Forms Comprising The Same
#514Dosage forms for movement disorder treatment
#515ODOURLESS GARLIC SUPPLEMENT COMPRISING AN ENTERIC COATING AND A DEODORISING LAYER
#516Enteric Sustained-Release Tablet Comprising Paroxetine
#517Low Dosage Forms Of Risedronate Or Its Salts
#518Low Dosage Forms Of Risedronate Or Its Salts
#519Bupropion hydrobromide and therapeutic applications
#520Ppar-Gamma Agonists for Improvement of Cognitive Function in Apoe4 Negative Patients
#521Dosage forms of active ingredients containing hydroxystilbene for treating menopausal complaints
#522Combination of Rosiglitazone and Donepezil for Improvement of Cognitive Function
#523CONTROLLED RELEASE NISOLDIPINE COMPOSITIONS
#524Multiparticulate Pharmaceutical form Comprising Pellets with a Substance Having a Modular Effect in Relation to Active Ingredient Release
#525Formulations of Pyridoxal-5'-Phosphate and Methods of Preparation
#526Therapeutic materials and methods
#527Pharmaceutical compositions for sleep disorders
#528Sugar-coated agent
#529Stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof
#530Oral formulations
#531SIROLIMUS NANODISPERSION
#532Film-coated solid dosage form
#533Gastric retention system
#534SUSTAINED RELEASE PHARMACEUTICAL PREPARATIONS AND METHODS FOR PRODUCING THE SAME
#535Controlled-Release Pharmaceutical Composition and Method for Producing the Same
#536Stable solid dispersion of a derivative of vinca alkaloid and process for manufacturing it
#537Modified release formulations of a bupropion salt
#538Bupropion hydrobromide and therapeutic applications
#539Controlled release nisoldipine compositions
#540Injectable sustained release delivery devices
#541STABLE TABLET DOSAGE FORMS OF PROTON PUMP INHIBITORS
#542Controlled Release Formulations
#543Modified release formulations of a bupropion salt
#544COLON-TARGETED ORAL FORMULATIONS OF CYTIDINE ANALOGS
#545Modified release formulations of a bupropion salt
#546Pharmaceutical compositions of ilaparazole
#547Pharmaceutical compositions and methods for improved bacterial eradication
#548Modified release formulations of a bupropion salt
#549Modified release formulations of a bupropion salt
#550Modified release formulations of a bupropion salt
#551Modified release formulations of a bupropion salt
#552Modified release formulations of a bupropion salt
#553Edible holographic products, particularly pharmaceuticals and methods and apparatus for producing same
#554Sustained Release Formulation Containing Selective Serotonin Reuptake Inhibitor and Method for the Preparation Thereof
#555Modified release formulations of a bupropion salt
#556MODIFIED RELEASE FORMULATIONS OF A BUPROPION SALT
#557Modified release formulations of a bupropion salt
#558Compression Coated Tablet Comprising Sumatriptan
#559Modified release formulations of a bupropion salt
#560Hydrophilic/lipophilic polymeric matrix dosage formulation
#561Method for dip coating dosage forms
#562Novel formulation of pyridoxal-5'-phosphate and method of preparation
#563Oral pharmaceutical composition for targeted transport of a platinum complex into the colorectal region, method for producing and use as medicament thereof
#564Controlled Release Pharmaceutical Formulation
#565Dosage Form Having Polymorphic Stability
#566Dosage forms having a randomized coating
#567Compositions Comprising Organic Compounds
#568Stable oral formulation containing benzimidazole derivative
#569Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
#570Parathyroid hormone (pth) containing pharmaceutical compositions for oral use
#571Controlled release metformin formulations
#572Dosage forms for movement disorder treatment
#573Orally administered pharmaceutical composition
#574Composition for releasing a weak base for an extended period of time
#575Extended release dosage form
#576Controlled-release pharmaceutical composition and method for producing the same
#577Nutritional supplement for the enhancement of the health of the liver
#578Nutritional supplement for the enhancement of the health of the liver
#579Adhesives and their applications
#580Oral compositions containing a salivation inducing agent
#581Sustained-release formulation and uses thereof
#582Sustained release oral formulations
#583Modified release formulations of a bupropion salt
#584Magnesium salt proton pump inhibitor dosage forms
#585Benzimidazole formulation
#586Asymmetrically coated table
#587Dosage forms for movement disorder treatment
#588Pharmaceutical formulation comprising a pyrimidine-a-one derivative coated with an enteric polymer
#589Specific time-delayed burst profile delivery system
#590Methods for the dispersion of water-soluble of hydrophilic substances in a supercritically pressurized fluid
#591Pharmaceutical formulations of amyloid inhibiting compounds
#592Localized controlled absorption of statins in the gastrointestinal tract for achieving high blood levels of statins
#593Pharmaceutical formulations of amyloid inhibiting compounds
#594SYSTEMS, METHODS AND APPARATUSES FOR MANUFACTURING DOSAGE FORMS
#595Dosage form containing pantoprazole as active ingredient
#596Modified release tablet of bupropion hydrochloride
#597Dosage form containing (s)-pantoprazole as active ingredient
#598Stable tablet dosage forms of proton pump inhibitors
#599Programmed drug delivery system
#600Dual controlled release dosage form